Literature DB >> 12411424

Respiratory actions of vanilloid receptor agonists in the nucleus of the solitary tract: comparison of resiniferatoxin with non-pungent agents and anandamide.

Dominic P Geraghty1, Stuart B Mazzone.   

Abstract

1. Activation of vanilloid receptors on sensory nerve terminals in the commissural nucleus of the solitary tract (cNTS) of rats with capsaicin, produces respiratory slowing. In this study, we used microinjection techniques employing pungent and non-pungent vanilloids to further characterize vanilloid receptors in the cNTS. 2. Microinjection of the pungent vanilloid, resiniferatoxin (RTX), into the cNTS of urethane-anaesthetized rats, dose-dependently reduced respiratory rate without affecting tidal volume. RTX was 20 fold more potent at slowing respiration ( approximately ED(50), 100 pmol) than capsaicin ( approximately ED(50), 2 nmol). Doses of RTX greater than 100 pmol caused either irregular (dyspnoeic) breathing or terminal apnoea (>250 pmol). The respiratory slowing response to RTX (75 pmol), was dose-dependently attenuated by injecting RTX (but not vehicle) into the same site 60 min earlier. 3. The non-pungent phorbol derivative of RTX, phorbol 12-phenylacetete 13-acetate 20-homovanillate (PPAHV, 0.1-1 nmol), also slowed respiration (ED(50), approximately 1 nmol) and almost abolished response to RTX (75 pmol) injected into the same site 60 min later. 4. In contrast to RTX, PPAHV and capsaicin, the putative endogenous vanilloid receptor agonist, arachidonyl ethanolamide (AEA), and non-pungent capsaicin derivative, olvanil, had no direct effect on respiration. However, both AEA and olvanil dose-dependently reduced the respiratory response to injection of RTX (75 pmol) 60 min later into the same site (EC(50)s, for AEA and olvanil, approximately 2 and 0.2 nmol, respectively). 5. These studies suggest that both pungent and non-pungent vanilloids interact with vanilloid receptors in the cNTS. However, whereas RTX and PPAHV activate and subsequently desensitize vanilloid receptors on sensory nerve terminals in the cNTS, olvanil and AEA fail to activate despite readily desensitizing responses to RTX in this region.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12411424      PMCID: PMC1573554          DOI: 10.1038/sj.bjp.0704931

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  38 in total

1.  Respiratory actions of tachykinins in the nucleus of the solitary tract: effect of neonatal capsaicin pretreatment.

Authors:  S B Mazzone; D P Geraghty
Journal:  Br J Pharmacol       Date:  2000-03       Impact factor: 8.739

2.  Functional and desensitizing effects of the novel synthetic vanilloid-like agent 12-phenylacetate 13-acetate 20-homovanillate (PPAHV) in the perfused rat hindlimb.

Authors:  C D Griffiths; M A Vincent; A Szallasi; E Q Colquhoun; D P Geraghty
Journal:  Br J Pharmacol       Date:  2000-12       Impact factor: 8.739

3.  Temperature-dependent activation of recombinant rat vanilloid VR1 receptors expressed in HEK293 cells by capsaicin and anandamide.

Authors:  J Sprague; C Harrison; D J Rowbotham; D Smart; D G Lambert
Journal:  Eur J Pharmacol       Date:  2001-07-06       Impact factor: 4.432

4.  Brain stem projections of sensory and motor components of the vagus complex in the cat: II. Laryngeal, tracheobronchial, pulmonary, cardiac, and gastrointestinal branches.

Authors:  M Kalia; M M Mesulam
Journal:  J Comp Neurol       Date:  1980-09-15       Impact factor: 3.215

5.  The endogenous cannabinoid agonist, anandamide stimulates sensory nerves in guinea-pig airways.

Authors:  R C Tucker; M Kagaya; C P Page; D Spina
Journal:  Br J Pharmacol       Date:  2001-03       Impact factor: 8.739

6.  Sensitivity of vagal afferent endings to chemical irritants in the rat lung.

Authors:  C Y Ho; Q Gu; Y S Lin; L Y Lee
Journal:  Respir Physiol       Date:  2001-09

7.  Cannabinoid activation of recombinant and endogenous vanilloid receptors.

Authors:  V Ralevic; D A Kendall; J C Jerman; D N Middlemiss; D Smart
Journal:  Eur J Pharmacol       Date:  2001-07-27       Impact factor: 4.432

8.  Iodo-resiniferatoxin, a new potent vanilloid receptor antagonist.

Authors:  P Wahl; C Foged; S Tullin; C Thomsen
Journal:  Mol Pharmacol       Date:  2001-01       Impact factor: 4.436

9.  Stimulation of pulmonary vagal C-fibres by anandamide in anaesthetized rats: role of vanilloid type 1 receptors.

Authors:  You Shuei Lin; Lu-Yuan Lee
Journal:  J Physiol       Date:  2002-03-15       Impact factor: 5.182

10.  Distribution of mRNA for vanilloid receptor subtype 1 (VR1), and VR1-like immunoreactivity, in the central nervous system of the rat and human.

Authors:  E Mezey; Z E Tóth; D N Cortright; M K Arzubi; J E Krause; R Elde; A Guo; P M Blumberg; A Szallasi
Journal:  Proc Natl Acad Sci U S A       Date:  2000-03-28       Impact factor: 11.205

View more
  6 in total

1.  Cannabinoid receptor activation in the rostral ventrolateral medulla oblongata evokes cardiorespiratory effects in anaesthetised rats.

Authors:  James R Padley; Qun Li; Paul M Pilowsky; Ann K Goodchild
Journal:  Br J Pharmacol       Date:  2003-08-04       Impact factor: 8.739

Review 2.  Anandamide and vanilloid TRPV1 receptors.

Authors:  Ruth A Ross
Journal:  Br J Pharmacol       Date:  2003-09-29       Impact factor: 8.739

3.  An overview of the sensory receptors regulating cough.

Authors:  Stuart B Mazzone
Journal:  Cough       Date:  2005-08-04

Review 4.  Hot receptors in the brain.

Authors:  Hendrik W Steenland; Shanelle W Ko; Long-Jun Wu; Min Zhuo
Journal:  Mol Pain       Date:  2006-11-08       Impact factor: 3.395

5.  Peptide and lipid modulation of glutamatergic afferent synaptic transmission in the solitary tract nucleus.

Authors:  Michael C Andresen; Jessica A Fawley; Mackenzie E Hofmann
Journal:  Front Neurosci       Date:  2013-01-10       Impact factor: 4.677

Review 6.  The involvement of TRPV1 in emesis and anti-emesis.

Authors:  John A Rudd; Eugene Nalivaiko; Norio Matsuki; Christina Wan; Paul Lr Andrews
Journal:  Temperature (Austin)       Date:  2015-05-21
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.